GT Biopharma (OTCQB:GTBP) Dr. Raymond Urbanski sat down with Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. The clinical stage biopharmaceutical company is focused on the development and commercialization of immuno-oncology products based off its proprietary Tri-specific Killer Engager (TriKE), Tetra-specific Killer Engager (TetraKE) and bi-specific Antibody Drug Conjugate (ADC) technology platforms.
GT Biopharma unique technology targeting Lymphoma and Leukemia cell lines
Quick facts: GT Biopharma
Market Cap: $10.02 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE